Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review

Haiyan Li1 · Zongwen Shuai1

Received: 13 July 2021 / Accepted: 29 October 2021 / Published online: 8 November 2021
© The Author(s) 2021

Abstract
To evaluate the efficacy and safety of tocilizumab (TCZ) in the treatment of refractory Takayasu arteritis (TAK). Eleven refractory TAK patients treated with TCZ at the First Affiliated Hospital of Anhui Medical University between 2017 July and 2020 December were respectively analyzed. We also respectively analyzed the studies on TCZ efficacy in patients with TAK, from PubMed/MEDLINE, Elsevier Science Direct between January 2010 and April 2021. The median age of 11 patients was 34(19–46) years. After 3 months of TCZ, a significant drop was found in median NIH (3[2–5] at baseline vs 1[0–2] after 6 months; \( p < 0.05 \)), ITAS-2010 score (8.5[6–11] vs 6[1–10]; \( p < 0.05 \)). One (9%) patient experienced relapse during TCZ treatment. After withdrawal of TCZ, one patient (9%) underwent relapse and nine patients (81%) were spared of GC use. In literature review, a total of 211 patients (mean age 35 years) were analyzed, including 80 (38%) Chinese and 169 females (80%). Among the 211 patients, (154 patients) 73% achieved remission after the last infusion of TCZ; TAK relapsed in 6% of patients during TCZ treatment and 5% of the TCZ patients after the withdrawal of TCZ. A total of 95 types of adverse events were observed in the literature. Infection was the most common adverse effect, occurring in 50% of patients. TCZ could serve as an efficacious and safe agent for refractory TAK.

Keywords Takayasu arteritis · Tocilzumab · Interleukin-6 · C-reactive protein · Erythrocyte sedimentation rate

Introduction
Takayasu arteritis (TAK) is a major large vessel vasculitis involving the aorta, its major branches and the pulmonary arteries [1]. TAK is more prevalent in Asia and the Middle East than in other regions [2]. TAK predominantly affects the young women in their twenties or thirties [3]. Without early effective anti-inflammatory treatments, TAK patients may undergo relapse after continuous inflammation and vascular injury [4].

The pathogenesis of TAK remains unclear. Multiple studies have revealed the active roles of pro-inflammatory cytokines, including tumor necrosis factor α (TNFα) and interleukin-6 (IL-6). IL-6 level increases in the serum, so does its expression in the aorta [5, 6]. In addition, IL-6 can mark the activity of various diseases [7]. Therefore, baseline IL-6 level has been suggested to predict TAK relapse during a long-term follow-up [8]. Blockade of IL-6 signaling may counter TAK, which has been testified in experimental or clinical studies [9].

Glucocorticoids (GCs) can induce remission in almost 60% of TAK patients [10]. However, their long-term use results in various side effects, and brings with a high rate of relapse, even the dosage is tapered off gradually [11]. To overcome these events, traditional immunosuppressive agents are recommended [12]. However, those patients with a high disease activity may not react sufficiently.

Tocilizumab (TCZ), a humanized monoclonal antibody targeting the IL-6 receptor subunit alpha (IL-6Ra), has demonstrated a significant efficacy against rheumatoid arthritis. A number of observational studies and randomized control trials (RCTs) have reported that TCZ renders clinical improvement and curbs TAK progression [13]. More importantly, TCZ could alter the mural thickness of arteries affected, thereby facilitating the reduction of steroid dose [14, 15].
We report herein a retrospective study and a literature review on the efficacy and tolerance of TCZ in Chinese patients.

**Methods**

**Patients and methods**

**Patients**

This was a retrospective single-center study based on patients aged 16 or more at the moment of informed consent and recruited from the First Affiliated Hospital of Anhui Medical University between July 2017 and December 2020. The diagnosis was established according to the Indian Takayasu clinical activity score (ITAS2010). The data of patients’ clinical manifestations, laboratory indexes, imaging features and treatment outcomes at TCZ initiation, 3, 6 and 12 months were recorded. The dosage of GCs was 8 mg/kg (once a month, intravenous infusion).

**Clinical efficacy assessment and definition**

The clinical efficacy was determined as favorable changes in symptoms and signs, GC dosage and imaging features after TCZ treatment. Remission was defined as lack of clinical manifestations of active disease and daily prednisone dosage less than 10 mg/day with a NIH < 2. Relapse was defined as a condition, in which remission had been achieved, but disease turned active again, and treatment was needed.

**Search strategy**

From PubMed/MEDLINE, Elsevier Science Direct, we searched studies about TCZ in the treatment of TAK. All articles were limited to full text, English language, and publication date between January 2010 and April 2021. The keywords included TAK, TCZ, interleukin-6/IL-6. Studies with patients aged < 16 years and case reports with less than five subjects were excluded.

**Statistical analysis**

Continuous variables were presented as medians with ranges, and qualitative variables as frequencies with percentages. Fisher’s exact test was carried out to compare qualitative variables. We used independent samples t test to analyze continuous variables with normal distribution and the Mann–Whitney or Wilcoxon test to compare continuous variables with non-normal distribution. As appropriate, \( p < 0.05 \) was considered as statistically significant.

**Results**

**Patient characteristics**

A total of patients (one male, ten females) with TAK were included in the study. The mean age at disease onset was 34 years (ranges 19–46 years), similar to that reported in other TAK patients. The average duration of TAK before TCZ treatment was 32.3 months. Three patients discontinued TCZ after first infusion. Two patients refused TCZ due to high cost and one for neutropenia and pneumonia. The main parameters about disease activity are described in Table 1. The levels of acute inflammatory markers showed a remarkable decrease. After TCZ therapy for 6 months, C-reactive protein (CRP) decreased from 34.1 mg/L (13.3–55.1) to 0.6 mg/L (0.3–0.9), erythrocyte sedimentation rate (ESR) from 41.6 mm/h (29–49) to 10.5 mm/1 h (4.3–15.3). NIH scores declined significantly from 3 (2–5) to 1 (0–2) (\( p < 0.001 \)), ITAS2010 baseline from 7 (6–9) to 3 (1–5) (\( p < 0.001 \)). After a 6-month TCZ treatment, the dosage of GCs was reduced from 35.5 mg (30–50) to 3.1 mg (0–6.9) (Fig. 1). Eight patients (72.7%) achieved remission after six infusions of TCZ. Six patients (54.5%) developed vascular bruits. Four patients (36.4%) showed pulse weakness. Two patients showed a change of over 10 mmHg in blood pressure. Among the vascular manifestations in different studies, vascular bruits accounted for the biggest proportions (54.5%, 100%, 100%, 92.6%, respectively).

**Outcomes between post-treatment 6 months and 12 months**

Among the 8 patients, 3 patients (27%) continued to receive a total of 12 infusions. The other five patients (45%) received 6 months of TCZ and then GCs without TCZ. During the 12-month follow-up, seven patients (64%) were treated with only steroids, and one patient (9%) was not exposed to any other treatment (Table 1). All eight patients displayed no relapse.
A total of 211 patients (mean age 35 years) were reviewed, including 80 (38%) Chinese and 169 females (80%). Their demographic characteristics and clinical manifestations are concluded in Table 2. For Chinese patients, the median duration from disease onset to TCZ treatment was 12 (6–12) months, shorter than that reported in other populations (mean 16 months, ranges 11–24 months). Overall, type V vasculitis (45/110, 40.9%) was the most common type among all populations, followed by Type. In China, type I topped others (25/71, 35.2%), followed by type V.

**Table 1** Patients’ characteristics at initiation of TCZ and during follow-up

| Patients treated with TCZ (%(n)) | At initiation of TCZ | At 3 months | At 6 months | At 12 months |
|---------------------------------|----------------------|-------------|-------------|-------------|
| NIH score                       | 3                    | 2           | 1*          | 1           |
| ITAS 2010                       | 7                    | 3           | 3*          | 2           |
| Remission (%)                   | 0                    | 5(45.5)     | 8(72.7)     | 3(27.3)     |
| CRP                             | 34.1                 | 0.6*        | 0.6*        | 1.6*        |
| ESR                             | 41.6                 | 5.5*        | 8.0*        | 10.5*       |
| Prednisone (mg/day)             | 35.5                 | 4.2*        | 3.1*        | 3.1*        |
| Immunosuppressive drugs         |                      |             |             |             |
| AZP (n = 2); CTX (n = 3);       |                      |             |             |             |
| MTX (n = 2); MMF (n = 2);       |                      |             |             |             |
| TK506 (n = 1)                   |                      |             |             |             |
| WBC (10^9/L)                    | 8.4                  | 10.7        | 9.74        | 8.2         |
| NE (10^9/L)                     | 5.1                  | 5.7         | 6.0         | 5.4         |
| LY (10^9/L)                     | 2.3                  | 3.3         | 3.0         | 2.2         |
| PLT (10^12/L)                   | 268.2                | 268.0       | 261.0       | 237.5       |
| NLR                             | 2.6                  | 1.7         | 2.1         | 3.5         |
| PLR                             | 139.7                | 80.9        | 88.7        | 106.8       |
| RBC (10^12/L)                   | 4.3                  | 4.3         | 4.4         | 4.4         |
| Hb (g/L)                        | 115                  | 122         | 121         | 139         |
| ALT (U/L)                       | 19.1                 | 16.5        | 19.3        | 18          |
| Glu (mmol/L)                    | 74.6                 | 55          | 55.3        | 58.8        |
| Glu (mmol/L)                    | 4.6                  | 4.5         | 4.7         | 5.1         |

*ALT alanine aminotransferase; Cr creatinine; CRP C-reactive protein; ESR erythrocyte sedimentation rate; Glu glucose; Hb hemoglobin; LY lymphocyte; NE neutrophil; NLR neutrophil-to-lymphocyte ratio; PLT platelets; PLR platelet-to-lymphocyte ratio; RBC red blood cell; WBC white blood cell

* p < 0.05

**Fig. 1** Daily prednisone dosage during a 12-month follow-up

**Literature review**

A total of 211 patients (mean age 35 years) were reviewed, including 80 (38%) Chinese and 169 females (80%). Their demographic characteristics and clinical manifestations are concluded in Table 2. For Chinese patients, the median duration from disease onset to TCZ treatment was 12 (6–12) months, shorter than that reported in other populations (mean 16 months, ranges 11–24 months). Overall, type V vasculitis (45/110, 40.9%) was the most common type among all populations, followed by Type. In China, type I topped others (25/71, 35.2%), followed by type V.
### Table 2: Main features of the onset before Tocilizumab therapy in patients with refractory Takayasu arteritis in literature

| Variables                                | This study | Abisror [16] | Goel [17] | Tombetti [18] | Canas [19] | Mekinian [20] | Loricera et al. [21] | Zhou et al. [15] | Mekinian [12] | Nakaoka [13] | Kilic [22] | Kong et al. [23] | Pan et al. [24] | Wu et al. [19] |
|------------------------------------------|------------|--------------|-----------|---------------|------------|---------------|----------------------|-----------------|---------------|-------------|-----------|-----------------|-----------------|----------------|
| *n*                                      | 11         | 5            | 10        | 7             | 8          | 14            | 8                    | 16              | 46            | 18          | 15         | 9                | 11              | 33             |
| Year                                     | 2018       | 2013         | 2013      | 2013          | 2014       | 2015          | 2016                 | 2017            | 2018          | 2018        | 2020      | 2018            | 2020            | 2021          |
| Female (%(n))                            | 82(9)      | 80(5)        | 90(9)     | 100(7)        | 100(8)     | 64(7)         | 100(8)               | 94(15)          | 76(35)        | 88.9(16)    | 86.7(13)  | 89(8)           | 91(10)          | 82(27)         |
| Age                                      | 32.3       | 54           | 24.5      | 24            | 31         | 42            | 34                   | 33.1            | 43            | 31.1        | 35         | 32.1             | 35.6            | 26             |
| Treatment duration prior TCZ (months)    | 12         | –            | 25.5      | 14            | 18         | 11            | 12                   | –               | 12            | 24          | 6          | 6                | 6               | 14             |
| Numano subtype (%(n))                   |            |              |           |               |            |               |                      |                 |               |             |            |                 |                 |                |
| I                                        | 54.5(6)    | –            | 30(3)     | –             | 12.5(1)    | –             | –                    | 43.7(7)         | –             | 11.1(3)     | –         | –                | 11.1(2)         | 30(10)         |
| II                                       | 9.1(1)     | 40(2)        | –         | 12.5(1)       | –          | –             | 25(4)                | –               | 27.8(5)       | –           | –         | –                | 22.4(4)         | 24(8)          |
| III                                      | 0          | –            | –         | –             | –          | –             | –                    | 0               | 16.7(3)       | –           | –         | –                | 0               | 3(1)           |
| IV                                       | 18.2(2)    | –            | –         | 12.5(1)       | –          | –             | 6.3(1)               | –               | 0             | –           | –         | –                | 3(1)            |                |
| V                                        | 18.2(2)    | 20(1)        | 70(7)     | –             | 12.5(1)    | –             | 25(4)                | –               | 44.4(8)       | –           | –         | 45.5(5)         | 39(13)          |                |
| Constitutional symptoms (%(n))           | 27.3(3)    |              | –         | 100(8)        | 64(7)      | 50(4)         | 56.3(9)              | 37.2(16)        | –             | 22.2(2)     | –         | –                | –               | –              |
| Limb claudication (%(n))                 | 18.2(2)    | –            | –         | –             | 12.5(1)    | 12.5(1)       | 43.8(7)              | 30.5(14)        | –             | 22.2(2)     | –         | –                | –               | –              |
| Neurological symptoms (%(n))             | 0          | –            | –         | –             | 25(2)      | –             | –                    | 18.3(3)         | –             | 33.3(3)     | –         | –                | 45(15)          |                |
| Vascular bruits (%(n))                   | 54.5(6)    |              | –         | –             | 50(4)      | –             | –                    | 100(16)         | 70(32)        | –           | –         | –                | 27(9)           |                |
| Pulse weakness (%(n))                    | 36.4(4)    | 20(1)        | –         | –             | 75(6)      | –             | –                    | 68.8(11)        | –             | 11.1(1)     | –         | –                | 30(10)          |                |
| Blood pressure differences > 10 mmHg (%(n))| 18.2(2)    | 20(1)        | –         | 50(4)         | –          | –             | 31.3(5)              | –               | –             | 22.2(2)     | –         | 100(11)         | –               |                |
| Immunosuppressive agents before TCZ      | AZP (n=2); CTX (n=3); MTX (n=2); MMF (n=2); Tac (n=1); Tripterygium glycosides (n=1); Thalidomide (n=1) |
| (AZP (n=2); CTX (n=3); MTX (n=1); MMF (n=2); Tac (n=1); Tripterygium glycosides (n=1); Thalidomide (n=1)) |

Note: Data from various studies are combined for comparison.
However, in other populations, type V accounted for the highest proportion (21/39, 54%), followed by type II (8/39, 20.5%). Vascular bruits were found in 67 (36.2%), constitutional symptoms in 12 (6.5%), limb claudication in 27 (14.6%), neurological symptoms in 23 (12.4%), pulse weakness in 32 (17.3%), and abnormal blood pressure in 24 (13%) patients. In China, vascular bruits were found in 31 (38.8%), constitutional symptoms in 12 (15%), limb claudication in 11 (13.8%), neurological symptoms in 21 (26.3%), and pulse weakness in 45 (39%) patients. Before the use of TCZ, more than half of the whole populations had received traditional immunosuppressive agents. MTX (47.4%) was the most frequently used. Prior to TCZ therapy, anti-TNFα was the most common, found in 89% (22/25) of all agents.

The already-reported responses to TCZ are summarized in Table 3. Among the 211 patients reviewed, 154 (73%) patients achieved clinical remission after TCZ treatment. Clinical remission was achieved in 82.5% of Chinese patients, and 67.2% in overseas patients, though assessment criteria of disease activity were different. The median TCZ duration was 7.9 (6–18) months. Among the 211 patients, (154 patients) 73% achieved remission after the last infusion of TCZ; TAK relapsed in 6% of patients during TCZ treatment and 5% of the TCZ patients after the withdrawal of TCZ. In China, only one (1.2%) patient experienced relapse during TCZ treatment and 5% of the TCZ patients after the withdrawal of TCZ. In China, only one (1.2%) patient experienced relapse during TCZ treatment, significantly fewer than those overseas (n = 4, p = 0.026). After withdrawal of TCZ, seven (8.8%) patients showed a relapse. All the studies in China revealed that the use of TCZ led to a significant reduction in the dosage of GCs. Most importantly, the percentage of TAK patients with relapse during TCZ treatment in our study was significantly lower than that in overseas studies.

The laboratory parameters are summarized in Table 3. The levels of acute phase inflammation markers, including CRP and ESR, varied a lot among all patients. Additionally, after TCZ treatment, the counts of white blood cells (WBs) and neutrophils (NEs) decreased, but the counts of lymphocytes (LYs), red blood cell (RBCs), platelets (PLTs) and hemoglobin increased, as compared with those before TCZ treatment.

Safety

One patient (9.1%) withdrew TCZ because of leukopenia and pulmonary infection in our study. A total of 95 types of adverse events were reported in the literature. Infection was the most common adverse effect, observed in 50% of patients. Liver enzyme abnormality was the least common adverse effect. Newly diagnosed or deteriorated neck pain was the second most common adverse event in

| Variables       | This study | Abisror [16] | Goel [17] | Tombetti et al. [18] | Canas et al. [19] | Mekhitarian et al. [20] | Zhou et al. [15] | Mekhitarian et al. [12] | Nakaoka et al. [13] | Kilic [22] | Kong et al. [23] | Wu et al. [19] |
|-----------------|-----------|--------------|-----------|----------------------|------------------|------------------------|-------------------|------------------------|-------------------|-------------|----------------|----------------|
| Biologic agents | IFX (n = 1) | IFX (n = 1) | IFX (n = 1) | IFX (n = 1) | IFX (n = 1) | IFX (n = 1) | IFX (n = 1) | IFX (n = 1) | IFX (n = 1) | IFX (n = 1) | IFX (n = 1) |
|                |           |             |           | ADA (n = 2)          | ADA (n = 2)      | ADA (n = 2)              | ADA (n = 2)       | ADA (n = 2)              | ADA (n = 2)       | ADA (n = 2) | ADA (n = 2) | ADA (n = 2) |
|                |           |             |           | IFX (n = 1)          | IFX (n = 1)      | IFX (n = 1)              | IFX (n = 1)       | IFX (n = 1)              | IFX (n = 1)       | IFX (n = 1) | IFX (n = 1) | IFX (n = 1) |
|                |           |             |           | TNFα antagonists (n = 2) | TNFα antagonists (n = 2) | TNFα antagonists (n = 2) | TNFα antagonists (n = 2) | TNFα antagonists (n = 2) | TNFα antagonists (n = 2) | TNFα antagonists (n = 2) | TNFα antagonists (n = 2) |
|                |           |             |           | ADA (n = 1)          | ADA (n = 1)      | ADA (n = 1)              | ADA (n = 1)       | ADA (n = 1)              | ADA (n = 1)       | ADA (n = 1) | ADA (n = 1) | ADA (n = 1) |
|                |           |             |           | RTX (n = 1)          | RTX (n = 1)      | RTX (n = 1)              | RTX (n = 1)       | RTX (n = 1)              | RTX (n = 1)       | RTX (n = 1) | RTX (n = 1) | RTX (n = 1) |

| AZP | Azathioprine; CYC | Cyclosporine; CTX | cyclophosphamide; LEF | Leflunomide; MTX | Methotrexate; MOF | Mycophenolate mofetil; SIR | sulfasalazine; Tac | Tacrolimus; IFX |
|-----|-------------------|--------------------|-----------------------|------------------|-------------------|--------------------------|-------------------|------------------|
| (n = 1) | Infliximab | (n = 1) | (n = 1) | (n = 1) | (n = 1) | (n = 1) | (n = 1) | (n = 1) | (n = 1) | (n = 1) | (n = 1) |
| (n = 1) | ADA | (n = 2) | (n = 2) | (n = 2) | (n = 2) | (n = 2) | (n = 2) | (n = 2) | (n = 2) | (n = 2) | (n = 2) | (n = 2) |
| (n = 1) | RTX | (n = 1) | (n = 1) | (n = 1) | (n = 1) | (n = 1) | (n = 1) | (n = 1) | (n = 1) | (n = 1) | (n = 1) | (n = 1) |
Chinese patients (20%). Other adverse effects included skin rash, liver enzyme abnormality, gastro-intestinal disorders, and neoplasms. No serious adverse effects and death were observed. Figure 2 shows the adverse effects in other studies and ours.

Discussion

Our study clarified the potential efficacy of TCZ in Chinese patients with refractory TAK in the active phase. During the 6-month follow-up, TCZ significantly decreased the ESR, CRP, and NIH scores as well as ITAS 2010 in patients with TAK. The present study is possibly the first to elegantly describe the characteristic of global TAK patients and the efficiency of TCZ using the diagnostic standard in 1990 American College of Rheumatology (ACR). Consistent with previous overseas studies, the present study held that TAK mainly attacks the young female patients [26]. Types I and V showed up in more than 50% of Chinese TAK patients. In other countries, types II and V were the most common. In either China or other countries, the vascular bruits are the most common vascular sign.

In our study, TCZ was used as an optional therapy for those patients who failed to adequately respond to GCs and immunosuppressive agents (100%) or anti-TNF agents (9.1%). Patients with TAK took the GCs combined with disease-modifying rheumatic drugs (DMARDS) as the first-line strategy. CTX and MTX were the most common DMARDS (in 27.8% and 24.1%, respectively) to be combined with GCs. However, Ohigashi has reported that more than 50% of TAK patients treated with GC monotherapy suffered from disease flare during GC dosage tapering [27]. Considering the high rate of relapse after GC therapy, immunosuppressive agents and/or biological agents are supplemented to provide more benefits. In our analysis, 45 TAK patients lacking clinical response to GCs and anti-TNF agents benefited from TCZ therapy.

The management of TAK has not been standardized. One study has shown that TCZ and anti-TNFα agents triggered similar partial and complete responses at post-treatment 3, 6 and 12 months [12]. Our study demonstrated that TCZ was usually prescribed as an optional drug after traditional immunosuppressive or anti-TNFα agents failed to produce desirable effects. Anti-TNFα agents are used as the first choice, but cannot induce remission in more than 10% of patients. However, a 6-month treatment of TCZ realized clinical remission in our analysis. Tombetti has reported the similar results in seven patients with refractory TAK from a single center [18]. Moreover, Shuai et al. found that TCZ, compared to anti-TNFα agents, achieved a higher remission rate and a lower relapse rate (70% vs 65%, 17% vs 20%, respectively) [28].

The efficacy of TCZ in treating newly diagnosed TAK patients or refractory TAK patients has been explored in European randomized trials and prospective trials [26, 29]. As shown in our review, all the studies reported significant improvement in disease activity (Kerr score or NIH or ITAS2010) as well as the laboratory parameters (mainly CRP and ESR). In TAK management guidelines, inflammatory markers are recommended as tools to monitor disease activity [30]. In the presence of TCZ, the dosage of GCs can be reduced [31]. TCZ can also increase the event-free survival rate [12]. In the present study, one patient maintained remission, although GCs dosage was reduced after a 6-month treatment of TCZ. Lo Gullo et al. also reported that a TAK patients resistant to traditional immunosuppressive drugs achieved a steroid-sparing condition through subcutaneous administration of TCZ [32], suggesting that TCZ can reduce the dosage of traditional immunosuppressive drugs, while maintain the remission in TAK patients. Our study also supported that after withdrawal of TCZ; the disease activity could be well controlled [14]. The only prospective study of TAK reported a high rate of remission of 85% [26]. In contrast, the remission rate (73%) in our study was significantly lower, probably because three patients discontinued TCZ use due to its high cost. TCZ induced complete clinical remission in 86% of Chinese patients, a rate close to that reported in a multicenter retrospective study [12]. In a previous study, the remission rate in DMARDs-treated patients was lower than that in naïve-treated patients, but their relapse rates were similar. In the present study, the relapse rate during TCZ treatment was much lower than that reported in the prospective study.

IL-6 is actively involved in the pathology of anemia of patients with TAK [15]. Zhang et al. reported that anemia was more likely to occur in young or female TAK patients with high disease activity [33]. The present study also supported that the level of hemoglobin increases with the reduction of acute inflammatory markers in TAK patients under remission.

Several studies of rheumatic disease revealed the close relationship of disease activity with platelet-to-lymphocyte ratio (PLR) as well as neutrophil-to-lymphocyte ratio (NLR) [34–36]. However, scant literature has analyzed the link between PLR/NLR and TCZ efficacy. This link was illustrated in the present study. Pan et al. suggested that a higher NLR indicated a higher disease activity in patients with TAK [35]. In the literature analysis, TAK patients showed decreased counts of leucocytes, NE and PLT, and increased counts of lymphocytes. NLR and PLR declined after the patients achieved remission, though without obvious discrepancies between Chinese and other populations. The pathological mechanism of TAK may involve the
| Characteristics          | This study | Abisror [16] | Goel [17] | Tombetti [18] | Canas [19] | Mekinian [20] | Loricera [21] | Zhou et al. [15] | Mekinian [12] | Nakaoka [13] | Kilic [22] | Pan et al. [23] | Kong et al. [24] | Wu et al. [25] |
|-------------------------|------------|--------------|-----------|---------------|------------|---------------|---------------|----------------|----------------|--------------|-------------|----------------|----------------|---------------|
| Median duration TCZ (months) | 6          | –            | 7.9       | 14            | 18         | 6             | 15.5          | 24.5           | 18             | 14           | 15          | 6             | 6              | 6              |
| Remission on TCZ (%(n))  | 73(8)      | 50(2)        | 90(9)     | 57(4)         | 100(8)     | 50(7)         | 87.5(7)       | 81(13)         | 89(41)        | 55.6(10)   | 87(13)     | 100(11)        | 100(9)         | 70(23)        |
| Relapse during therapy (%(n)) | 0(0)      | 20(1)        | 0         | 57(4)*        | 0(0)       | –             | –             | 0(0)           | –              | 44(8)*      | 13(2)       | –             | 0(0)           | 9(1)          |
| Relapse after withdrawal of TCZ (%(n)) | 9.1(1) | –            | 30(3)     | –             | –          | –             | 12.5(1)       | –              | –             | –           | –           | –             | 43(6)          |
| Steroid-sparing (%(n))   | 9.1(1)     | 20(1)        | 10(1)     | –             | –          | –             | 6(1)          | –              | –             | –           | 45(5)       | –             | –              |
| Kerr score (before/after) | 3/0        | –            | –         | –             | –          | –             | –             | –              | –             | –           | 2/0         | 8/1           | –              |
| NIH (before/after)       | 3/1        | –            | –         | –             | –          | –             | –             | 3/0            | –              | –           | –           | –             | 2/2            |
| ITAS2010 (before/after)  | 7/3        | –            | 4/1       | –             | –          | –             | –             | –              | –             | –           | 9/1         | 5.67/2.67     | –              |
| Prednisone (mg/day) (before/after) | 35.5/4.2 | –            | 24/5.4    | 10/6.2        | 43.8/6.9   | 12.5/10       | 42.5/2.5      | 24.8/7.9       | 15/4          | –           | 16.2/7.1   | 7.5/2.5       | 30.0/10.0      | 30.0/15       |
| CRP (mg/L) (before/after) | 34.1/0.6   | 14.9/8.0     | –         | 13/2          | 2.3/1.0    | 24/2          | 3.1/0.2       | 28.9/0.6       | 23/1          | –           | 39.8/7.9   | 3.2/0.72      | 53.3/12.7      | 11.2/0.9      |
| ESR (mm/h) (before/after) | 41.6/5.5   | 36.7/6.9     | –         | 34/4          | 39.8/13.1  | –             | 40/3          | 39/6           | –             | –           | 26/3        | 13/2         | 73.9/9.4       | 41.0/4.0      |
| Characteristics   | This study | Abisnor [16] | Goel [17] | Tombetti [18] | Canas [19] | Mekinian [20] | Loricera | Zhou et al. [15] | Mekinian [12] | Nakaoka | Kilic [22] | Pan et al. [23] | Kong et al. [24] | Wu et al. [25] |
|-------------------|------------|--------------|-----------|--------------|-----------|--------------|----------|-----------------|--------------|---------|-----------|---------------|---------------|-------------|
| WBC (10^9/L)      | 8.4/8.2    | –            | –         | 9.25/9.01    | –         | –            | –        | 10.0/8.1        | –            | –       | –         | –             | –             | –           |
| NE (10^9/L)       | 5.1/5.0    | –            | –         | 5.53/5.60    | –         | –            | –        | –               | 4.7/4.6      | –       | –         | –             | –             | –           |
| LY (10^9/L)       | 2.3/2.4    | –            | –         | 2.99/2.63    | –         | –            | –        | –               | 2.4/2.4      | –       | –         | –             | –             | –           |
| PLT (10^12/L)     | 268.2/237.5| –            | –         | 370/277      | –         | –            | –        | 259.7/222.6     | 360.0/253.6  | –       | –         | –             | –             | –           |
| NLR (before/after)| 2.6/3.5    | –            | –         | 1.9/2.2      | –         | –            | –        | –               | 2.0/1.9      | –       | –         | –             | –             | –           |
| PLR (before/after)| 139.7/106.8| –            | –         | 123.7/105.3  | –         | –            | –        | 108.2/92.8      | 124.1/79.3   | –       | –         | –             | –             | –           |
| RBC (10^12/L)     | 4.3/4.4    | –            | –         | –            | –         | –            | –        | –               | –            | –       | –         | –             | –             | –           |
| Hb (g/L)          | 115/139    | –            | –         | 105/110      | –         | –            | –        | –               | –            | –       | –         | –             | –             | –           |

*CRP* C-reactive protein; *ESR* erythrocyte sedimentation rate; *RBC* red blood cell; *Hb* hemoglobin; *WBC* white blood cell; *NE* neutrophil; *LY* lymphocyte; *PLT* platelets; *NLR* neutrophil-to-lymphocyte ratio; *PLR* platelet-to-lymphocyte ratio

*p < 0.05*
recruitment and infiltration of neutrophils in the aorta following arterial inflammation [37].

In our literature, 11 (5%) patients received 18F-FDG PET/CT imaging to assess the disease activity of TAK. However, in China, 18F-FDG-PET was not extensively recommended to TAK patients because of high fees of 18F-FDG-PET. Recent studies recommended the 18F-FDG-PET for monitoring the disease activity of TAK including assessment of the recurrence of TAK, since 18F-FDG-PET showed the simultaneous changes of inflammation in arterial walls and clinical course under the therapy of TCZ [38, 39]. In summary, FDG-PET is a promising checking method to aid the clinical evaluation of disease activity.

The safety of TCZ has been validated in various autoimmune diseases [40–42]. In our study, neutropenia and severe pneumonia were observed in one patient (9.1%) and this patient discontinued the use of TCZ because of adverse effects. In our study, adverse events were found in 32.5% of Chinese TAK patients, with severe infections accounting for 16%. These infections may arise from leukopenia and neutropenia. Additionally, high-dose or continuous GCs treatment may increase the risk of recurrent infections by bacteria or fungus, such as invasive Aspergillosis [43]. In our study, only one patient suffered from pulmonary bacterial infection originating from neutropenia. This condition has been revealed in other studies [43–45].

Another adverse effect is severe neck pain, which has also been reported in previous studies [15]. Zhou et al. observed that patients with new TAK onset or deteriorated neck pain had higher rates of constitutional symptoms and required higher GC dosage [15]. A significantly lower Hb concentration was also detected in such patients than in those without neck pain. Infections are more common in Chinese patients, but abnormal liver enzymes, new TAK onset or deteriorated neck pain appeared more frequently in other populations. No death was observed in our study.

This study has several limitations. First, the patients were only recruited from a single center. Hence, advanced studies are needed to verify the benefits of TCZ in contrast to traditional DMARDs.

**Conclusion**

TCZ demonstrated obvious efficacy and safety in naïve-treated patients and patients with refractory TAK. TCZ could also induce a long period of remission. However, large-scale open-label and randomized trials are required to assess its long-term efficacy and safety and figure out an optimal scheduling.

**Acknowledgements** We would like to thank the members of the Department of Rheumatology and Immunology in the First Affiliated Hospital of Anhui Medical University.

**Authors’ contributions** Study design: HL and ZS. Collection and interpretation of data: HL. Manuscript writing: HL and ZS. Funding provider: ZS. All authors have read and approved the final manuscript.

**Funding** This study is supported by National Natural Science Foundation of China (Number: 8187061400).

**Declarations**

**Conflict of interest** All authors have no conflict of interests associated with this study.

**Ethical approval** All participants offered written informed consent. The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and approved by The Committee on Medical Ethics of the First Affiliated Hospital of Anhui Medical University.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Tombetti E, Mason JC (2019) Takayasu arteritis: advanced understanding is leading to new horizons. Rheumatology (Oxford) 58(2):206–219
2. Onen F, Akkoç N (2017) Epidemiology of Takayasu arteritis. Presse Med 46(7–8 Part 2):e197–e203
3. Mason JC (2010) Takayasu arteritis—advances in diagnosis and management. Nat Rev Rheumatol 6(7):406–415
4. Direskeneli H (2017) Clinical assessment in Takayasu’s arteritis: major challenges and controversies. Clin Exp Rheumatol 35 Suppl 103(1):189–193
5. Berger CT, Rebholz-Chaves B, Recher M, Manigold T, Daikeler T (2019) Serial IL-6 measurements in patients with tocilizumab-treated large-vessel vasculitis detect infections and may predict early relapses. Ann Rheum Dis 78(7):1012–1014
6. Pulsatelli L, Boiardi L, Assirelli E, Pazzola G, Muratore F, Addimanda O, Dolzani P, Versari A, Casi, Magliani L, Pignotti E, Pipitone N, Croci S, Meliconi R, Salvarani C (2017) Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study. Clin Exp Rheumatol 35 Suppl 103(1):102–110
7. Tamura N, Maejima Y, Tezuka D, Takamura C, Yoshikawa S, Ashikaga T, Hirao K, Isobe M (2017) Profiles of serum cytokine levels in Takayasu arteritis patients: potential utility as biomarkers for monitoring disease activity. J Cardiol 70(3):278–285
8. Sun Y, Kong X, Cui X, Dai X, Ma L, Chen H, Chen R, Lv P, Lin J, Huang Q, Jin X, Jiang L (2020) The value of interleukin-6 in predicting disease relapse for Takayasu arteritis during 2-year follow-up. Clin Rheumatol 39(11):3417–3425
9. Kong X, Ma L, Ji Z, Dong Z, Zhang Z, Hou J, Zhang S, Ma L, Jiang L (2018) Pro-fibrotic effect of IL-6 via aortic adventitial fibroblasts indicates IL-6 as a treatment target in Takayasu arteritis. Clin Exp Rheumatol 36(1):62–72
10. Schmidt J, Kermani TA, Bacani AK, Crowson CS, Cooper LT, Matteson EL, Warrington KJ (2013) Diagnostic features, treatment, and outcomes of Takayasu arteritis in a US cohort of 126 patients. Mayo Clin Proc 88(8):822–830
11. Maksimowicz-McKinnon K, Clark TM, Hoffman GS (2007) Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 56(3):1000–1009
12. Mekinian A, Resche-Rigon M, Comarmond C, Soriano A, Constantin J, Alric L, Jego P, Busato F, Cabon M, Dhoie R, Estibaliz L, Kone-Paut I, Landron C, Lavigne C, Lioger B, Michaud M, Pignotti E, Pipitone N, Croci S, Meliconi R, Salvarani C (2017) Interleukin-6 and soluble interleukin-6 receptor are elevated in large-vessel vasculitis: a cross-sectional and longitudinal study. Clin Exp Rheumatol 35 Suppl 103(1):102–110
13. Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77(3):348–354
14. Saito S, Okuyama A, Okada Y, Shibata A, Sakai R, Kurasawa T, Kondo T, Takei H, Amano K (2019) Tocilizumab monotherapy for large vessel vasculitis: results of 104-week treatment of a prospective, single-centre, open study. Rheumatology (Oxford) 59(7):1617–1621
15. Zhou J, Chen Z, Li J, Yang Y, Zhao J, Chen H, Liu M, Sun F, Li M, Tian X, Zeng X (2017) The efficacy of tocilizumab for the treatment of Chinese Takayasu’s arteritis. Clin Exp Rheumatol 35 Suppl 103(1):171–175
16. Abisror N, Mekinian A, Lavigne C, Vandenbende MA, Soussan M, Fain O, Club Rhumatismes et Inflammation, SNFMI (2013) Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev 12(12):1143–1149
17. Goel R, Danda D, Kumar S, Joseph G (2013) Rapid control of disease activity by tocilizumab in 10 “difficult-to-treat” cases of Takayasu arteritis. Int J Rheum Dis 16(6):754–761
18. Tombetti E, Franchini S, Papa M, Sabbadini MG, Baldissera E (2013) Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol 40(12):2047–2051
19. Canas CA, Canas F, Izquierdo JH, Echeverri AF, Mejia M, Bonilla-Abadía F, Tobón GJ (2014) Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J Clin Rheumatol 20(3):125–129
20. Mekinian A, Comarmond C, Resche-Rigon M, Mirault T, Kahn JE, Lambert M, Sibilia J, Neel A, Cohen P, Hie M, Berthier S, Marie I, Lavigne C, Anne Vandenbende M, Muller G, Amoura Z, Devilliers H, Abad S, Hamidou M, Guilleuin L, Dhoie R, Godeau B, Messas E, Cacoub P, Fain O, Saadoun D (2015) Efficacy of biological-targeted treatments in Takayasu arteritis: multicenter, retrospective study of 49 patients. Circulation 132(18):1693–1700
21. Loriceria J, Blanco R, Hernandez JL, Castaneda S,umbria A, Ortego N, Bravo B, Freire M, Melchor S, Minguet M, Salvatiera J, Gonzalez-Vela C, Calvo-Rio V, Santos-Gomez M, Pina T, Gonzalez-Gay MA (2016) Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol 34(3 Suppl 97):S44–S53
22. Kilic L, Karadag O, Eroden A, Sari A, Aragman B, Yardimci GK, Firat E, Kalyoncu U, Aparas Bilgen S, Kiraz S, Ertenti I, Ackdogan A (2020) Anti-interleukin-6 (tocilizumab) therapy in Takayasu’s arteritis: a real life experience. Turk J Med Sci 50(1):31–36
23. Kong X, Zhang X, Lv P, Cui X, Ma L, Chen H, Liu H, Lin J, Jiang L (2018) Treatment of Takayasu arteritis with the IL-6R antibody tocilizumab vs. cyclophosphamide. Int J Cardiol 266:222–228
24. Pan L, Du J, Liu J, Liao H, Liu X, Guo X, Liang J, Han H, Yang L, Zhou Y (2020) Tocilizumab treatment effectively improves coronary artery involvement in patients with Takayasu arteritis. Clin Rheumatol 39(8):2369–2378
25. Wu S, Kong X, Cui X, Chen H, Ma L, Dai X, Ji Z, Yan Y, Huang Q, Sun Y, Jiang L (2021) Effectiveness and safety of tocilizumab in patients with refractory or severe Takayasu’s arteritis: a prospective cohort study in a Chinese population. Jt Bone Spine 88(5):105186
26. Mekinian A, Saadoun D, Vicaut E, Thierat S, Lioger B, Jego P, Bleibtreu A, Limal N, Connault J, Gottenberg JE, Lhorte P, Berton I, Delforge J, Ferreira-Maldent N, Perlat A, Talib Z, Vautier A, Bleibtreu A, Limal N, Connault J, Gottenberg JE, Lhorte P, Berton I, Delforge J, Ferreira-Maldent N, Perlat A, Talib Z, Vautier A, Bleibtreu A, Limal N, Connault J, Gottenberg JE, Lhorte P, Berton I, Delforge J, Ferreira-Maldent N, Perlat A, Talib Z, Vautier A (2013) Tocilizumab in refractory Takayasu arteritis: multicentre study in a Chinese population. Jt Bone Spine 88(5):105186
27. Ohigashi H, Tamura N, Ebana Y, Harigai M, Ashikaga T, Isobe M (2017) Effects of immunosuppressive and biological...
agents on refractory Takayasu arteritis patients unresponsive to glucocorticoid treatment. J Cardiol 69(5):774–778
28. Shuai ZQ, Zhang CX, Shuai ZW, Ge SL (2021) Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 25(1):250–262
29. Lee YH, Song GG (2019) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis. Ann Rheum Dis 78(1):e9
30. Maz M, Chung SA, Abril A, Langford CA, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA (2021) 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis. Arthritis Rheumatol 73(8):1349–1365
31. Decker P, Olivier P, Risse J, Zuily S, Wahl D (2018) Tocilizumab and refractory Takayasu arteritis: four case reports and systematic review. Autoimmun Rev 17(4):353–360
32. Lo Gullo A, Mandrala G, Aragona CO, Molica Colella A, Saitta A, Imbalzano E (2017) Subcutaneous administration of tocilizumab is effective in myointimal hyperplasia remodelling in refractory Takayasu arteritis. Reumatismo 69(4):184–188
33. Zhang Y, Zhang Q, Qu Y, Fan P, Liu YX, Zhang HM, Song L, Ma WJ, Wu HY, Cai J, Luo F, Zhou XL, Zheng DY, Liu LS (2019) Anemia in patients with Takayasu arteritis: prevalence, clinical features, and treatment. J Geriatr Cardiol 16(9):689–694
34. Gasparyan AY, Ayvazyan L, Mukanova U, Yessirkepov M, Kitas GD (2019) The platelet-to-lymphocyte ratio as an inflammatory marker in rheumatic diseases. Ann Med 43(4):345–357
35. Pan L, Du J, Li T, Liao H (2017) Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio associated with disease activity in patients with Takayasu’s arteritis: a case-control study. BMJ Open 7(4):e014451
36. Shadmanfar S, Masoumi M, Davatchi F, Shahram F, Akhlaghi M, Faezi ST, Kavosi H, Parsaee A, Moradi S, Balasi J, Moqaddam ZR (2021) Correlation of clinical signs and symptoms of Behcet’s disease with platelet-to-lymphocyte ratio (PLR) and neutrophil-to-lymphocyte ratio (NLR). Immunol Res 69(4):363–371
37. Inder SJ, Bobryshev YV, Cherian SM, Lord RS, Masuda K, Yutani C (2000) Accumulation of lymphocytes, dendritic cells, and granulocytes in the aortic wall affected by Takayasu’s disease. Angiology 51(7):565–579
38. Isobe M, Maeda Y, Saji M, Tateishi U (2021) Evaluation of tocilizumab for intractable Takayasu arteritis and (18)F-fluorodeoxyglucose-positron emission tomography for detecting inflammation under tocilizumab treatment. J Cardiol 77(5):539–544
39. Bardi M, Diamantopoulos AP (2019) EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice summary. Radiol Med 124(10):965–972
40. de Boysson H, Le Besnerais M, Blaison F, Daumas A, Jarrot PA, Perrin F, Tiettie N, Maria A, Duflau P, Gombert B, Samson M, Espitia O, Lambert M, Mekinian A, Aouba A, French Study Group for Large Vessel Vasculitis (2021) Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis. Arthritis Res Ther 23(1):143
41. Ferrante A, Ciccia F, Guggingo G, Colomba D, Triolo G (2016) Tocilizumab therapy for unresponsive pulmonary arterial hypertension in a patient with Takayasu arteritis. Scand J Rheumatol Suppl 45(3):251–252
42. Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, Muselman D, Brockwell L, Shittu E, Klearman M, Fleming TR (2020) Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: a randomized controlled trial. Arthritis Rheumatol 72(1):31–40
43. Cornillet A, Camus C, Nimubona S, Gandermer V, Tattevin P, Belleguic C, Chevrier S, Meunier C, Lebert C, Aumepe M, Caulet-Maugendre S, Faucheux M, Lelong B, Leray E, Guiuen C, Gangneux JP (2006) Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and non-neutropenic patients: a 6-year survey. Clin Infect Dis 43(5):577–584
44. Shaukat A, Bakri F, Young P, Hahn T, Ball D, Baer MR, Wetzler M, Slack JL, Loud P, Czuczman M, McCarthy PL, Walsh TJ, Segal BH (2005) Invasive filamentous fungal infections in allogeenic hematopoietic stem cell transplant recipients after recovery from neutropenia: clinical, radiologic, and pathologic characteristics. Mycopathologia 159(2):181–188
45. Zhirong Y, Wanqing L, Weihua P (1999) Case reports. Invasive pulmonary aspergillosis in non-neutropenic patients treated with liposomal amphotericin B. Mycoses 42(11–12):679–682

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.